Literature DB >> 1331223

Limited clinical usefulness of plasma corticotropin-releasing hormone, adrenocorticotropin and beta-endorphin measurements as markers of lung cancer.

A E Calogero1, G Minacapilli, A M Nicolosi, M L Moncada, A Mistretta, S F Latteri, P Polosa, R D'Agata.   

Abstract

We measured plasma corticotropin-releasing hormone (CRH), ACTH, beta-endorphin (beta-EP), and cortisol levels as possible tumor markers in a sequence of 103, randomly selected, patients with lung cancer but without the ectopic Cushing's syndrome and in 72 age- and sex-matched controls. Plasma CRH levels of cancer patients were similar to those of controls both in patients sampled in the morning or in the afternoon. On the other hand, plasma ACTH levels of cancer patients were significantly higher than control patients both in the morning and in the afternoon and showed a preserved circadian rhythm. However, about 35% of cancer patients sampled in the morning and about 60% of those sampled in the afternoon had ACTH levels within the 95% confidence interval (CI) of controls. Also plasma beta-EP levels were more elevated in cancer patients than controls in the morning but about 33% of them and about 80% of those sampled in the afternoon had beta-EP levels within the 95% CI of controls. Despite the higher plasma ACTH levels, cancer patients had cortisol plasma levels similar to controls with preserved circadian rhythm. In conclusion, although mean plasma ACTH and beta-EP were higher in patients affected by lung cancer, their measurements, as well as those of CRH, have practically no diagnostic value. Perhaps measurement of ACTH levels in the bronchial lavage may be more helpful.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331223     DOI: 10.1007/bf03344929

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Cushing's syndrome due to ectopic production of corticotropin-releasing factor.

Authors:  J L Belsky; B Cuello; L W Swanson; D M Simmons; R M Jarrett; F Braza
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

2.  Ectopic adrenocorticotropin syndrome caused by lung cancer that responded to corticotropin-releasing hormone.

Authors:  T Suda; M Kondo; R Totani; N Hashimoto; M Suzuki; T Imaki; Y Oba; N Tomori; F Yajima; T Sumitomo
Journal:  J Clin Endocrinol Metab       Date:  1986-11       Impact factor: 5.958

3.  Immunoreactive corticotropin and corticotropin-releasing factor in human hypothalamus, adrenal, lung cancer, and pheochromocytoma.

Authors:  T Suda; N Tomori; F Tozawa; H Demura; K Shizume; T Mouri; Y Miura; N Sasano
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

4.  Studies on ectopic ACTH-producing tumours. IV. CRF-like activity in tumour tissue.

Authors:  H Yamamoto; Y Hirata; S Matsukura; H Imura; M Nakamura; A Tanaka
Journal:  Acta Endocrinol (Copenh)       Date:  1976-05

5.  Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide.

Authors:  E Bork; M Hansen; P Urdal; E Paus; J J Holst; S Schifter; M Fenger; F Engbaek
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06

6.  ProACTH: use for early detection of lung cancer.

Authors:  A R Wolfsen; W D Odell
Journal:  Am J Med       Date:  1979-05       Impact factor: 4.965

7.  Adrenocorticotropin, calcitonin, and antidiuretic hormone as tumor markers in patients with bronchogenic carcinoma of various histological types.

Authors:  W Winkelmann; U Deuss; B Allolio; W Hummerich; D Kaulen; H Brosch; A Guyot; C Arnold
Journal:  Klin Wochenschr       Date:  1984-11-02

8.  Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion.

Authors:  T H Schürmeyer; P C Avgerinos; P W Gold; W T Gallucci; T P Tomai; G B Cutler; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

9.  Presence of corticotropin-releasing factor-like immunoreactivity in human tumors.

Authors:  I Wakabayashi; T Ihara; M Hattori; Y Tonegawa; T Shibasaki; K Hashimoto
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

10.  Rapid radioimmunoassay for corticotropin in unextracted human plasma.

Authors:  W E Nicholson; D R Davis; B J Sherrell; D N Orth
Journal:  Clin Chem       Date:  1984-02       Impact factor: 8.327

View more
  2 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

2.  Measurements of hormonal peptides in the bronchoalveolar fluid as tumor markers of lung cancer.

Authors:  A E Calogero; R Polosa; E Neville; R D'Agata
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.